130 related articles for article (PubMed ID: 22734433)
1. Brain targeting of Atorvastatin loaded amphiphilic PLGA-b-PEG nanoparticles.
Simşek S; Eroğlu H; Kurum B; Ulubayram K
J Microencapsul; 2013; 30(1):10-20. PubMed ID: 22734433
[TBL] [Abstract][Full Text] [Related]
2. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process.
Kim MS; Jin SJ; Kim JS; Park HJ; Song HS; Neubert RH; Hwang SJ
Eur J Pharm Biopharm; 2008 Jun; 69(2):454-65. PubMed ID: 18359211
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cellular uptake of folic acid-conjugated PLGA-PEG nanoparticles loaded with vincristine sulfate in human breast cancer.
Chen J; Li S; Shen Q; He H; Zhang Y
Drug Dev Ind Pharm; 2011 Nov; 37(11):1339-46. PubMed ID: 21524153
[TBL] [Abstract][Full Text] [Related]
4. Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier.
Chen YC; Hsieh WY; Lee WF; Zeng DT
J Biomater Appl; 2013 Mar; 27(7):909-22. PubMed ID: 22207601
[TBL] [Abstract][Full Text] [Related]
5. Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin.
Shen H; Zhong M
J Pharm Pharmacol; 2006 Sep; 58(9):1183-91. PubMed ID: 16945176
[TBL] [Abstract][Full Text] [Related]
6. Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure in treating hyperlipidemia.
Meena AK; Ratnam DV; Chandraiah G; Ankola DD; Rao PR; Kumar MN
Lipids; 2008 Mar; 43(3):231-41. PubMed ID: 18196308
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: preparation and in vitro evaluation.
Yang A; Yang L; Liu W; Li Z; Xu H; Yang X
Int J Pharm; 2007 Feb; 331(1):123-32. PubMed ID: 17097246
[TBL] [Abstract][Full Text] [Related]
8. Characterization of rhodamine loaded PEG-g-PLA nanoparticles (NPs): effect of poly(ethylene glycol) grafting density.
Essa S; Rabanel JM; Hildgen P
Int J Pharm; 2011 Jun; 411(1-2):178-87. PubMed ID: 21458551
[TBL] [Abstract][Full Text] [Related]
9. Ultrafine PEG-coated poly(lactic-co-glycolic acid) nanoparticles formulated by hydrophobic surfactant-assisted one-pot synthesis for biomedical applications.
Chu CH; Wang YC; Huang HY; Wu LC; Yang CS
Nanotechnology; 2011 May; 22(18):185601. PubMed ID: 21415469
[TBL] [Abstract][Full Text] [Related]
10. Small angle neutron scattering studies on the internal structure of poly(lactide-co-glycolide)-block-poly(ethylene glycol) nanoparticles as drug delivery vehicles.
Yang B; Lowe JP; Schweins R; Edler KJ
Biomacromolecules; 2015 Feb; 16(2):457-64. PubMed ID: 25539145
[TBL] [Abstract][Full Text] [Related]
11. Enhanced bioavailability of nano-sized chitosan-atorvastatin conjugate after oral administration to rats.
Anwar M; Warsi MH; Mallick N; Akhter S; Gahoi S; Jain GK; Talegaonkar S; Ahmad FJ; Khar RK
Eur J Pharm Sci; 2011 Oct; 44(3):241-9. PubMed ID: 21864678
[TBL] [Abstract][Full Text] [Related]
12. An HPLC method for the pharmacokinetic study of vincristine sulfate-loaded PLGA-PEG nanoparticle formulations after injection to rats.
Chen J; He H; Li S; Shen Q
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jul; 879(21):1967-72. PubMed ID: 21665557
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of sub-micron poly(D,L-lactide-co-glycolide) particles loaded with magnetite/maghemite nanoparticles.
Ngaboni Okassa L; Marchais H; Douziech-Eyrolles L; Cohen-Jonathan S; Soucé M; Dubois P; Chourpa I
Int J Pharm; 2005 Sep; 302(1-2):187-96. PubMed ID: 16099119
[TBL] [Abstract][Full Text] [Related]
14. Brain delivery and systemic effect of cationic albumin conjugated PLGA nanoparticles.
Xu F; Lu W; Wu H; Fan L; Gao X; Jiang X
J Drug Target; 2009 Jul; 17(6):423-34. PubMed ID: 19527113
[TBL] [Abstract][Full Text] [Related]
15. Preparation and therapeutic efficacy of polysorbate-80-coated amphotericin B/PLA-b-PEG nanoparticles.
Ren T; Xu N; Cao C; Yuan W; Yu X; Chen J; Ren J
J Biomater Sci Polym Ed; 2009; 20(10):1369-80. PubMed ID: 19622277
[TBL] [Abstract][Full Text] [Related]
16. Haloperidol-loaded intranasally administered lectin functionalized poly(ethylene glycol)-block-poly(D,L)-lactic-co-glycolic acid (PEG-PLGA) nanoparticles for the treatment of schizophrenia.
Piazza J; Hoare T; Molinaro L; Terpstra K; Bhandari J; Selvaganapathy PR; Gupta B; Mishra RK
Eur J Pharm Biopharm; 2014 May; 87(1):30-9. PubMed ID: 24560967
[TBL] [Abstract][Full Text] [Related]
17. The influence of covalently linked and free polyethylene glycol on the structural and release properties of rhBMP-2 loaded microspheres.
Lochmann A; Nitzsche H; von Einem S; Schwarz E; Mäder K
J Control Release; 2010 Oct; 147(1):92-100. PubMed ID: 20603166
[TBL] [Abstract][Full Text] [Related]
18. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease.
Hu K; Shi Y; Jiang W; Han J; Huang S; Jiang X
Int J Pharm; 2011 Aug; 415(1-2):273-83. PubMed ID: 21651967
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of oral bioavailability of atorvastatin calcium by self-emulsifying drug delivery systems (SEDDS).
Kadu PJ; Kushare SS; Thacker DD; Gattani SG
Pharm Dev Technol; 2011 Feb; 16(1):65-74. PubMed ID: 20088679
[TBL] [Abstract][Full Text] [Related]
20. Aspartic acid-based modified PLGA-PEG nanoparticles for bone targeting: in vitro and in vivo evaluation.
Fu YC; Fu TF; Wang HJ; Lin CW; Lee GH; Wu SC; Wang CK
Acta Biomater; 2014 Nov; 10(11):4583-4596. PubMed ID: 25050775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
